Results of Checkmate-025 study of Opdivo (nivolumab) in renal cell carcinoma published in NEJM- BMS

Bristol-Myers Squibb Company announced results from CheckMate-025, a Phase III study comparing Opdivo (nivolumab) to everolimus in advanced renal cell carcinoma (RCC) after prior anti-angiogenic treatment, showing a significant overall survival (OS) benefit for nivolumab. In the trial, nivolumab demonstrated a median OS benefit of 25 months compared to 19.6 months for everolimus. Clinical benefit for nivolumab was observed regardless of level of PD-L1 expression. The safety profile shown in CheckMate-025 is consistent with previously reported nivolumab trials. These data were presented as a late breaking abstract on 26 September during the 2015 European Cancer Congress (ECC) in Vienna. The results were also featured during the ECC press programme on September 25 and published in The New England Journal of Medicine (NEJM), representing the ninth publication in the NEJM for nivolumab.

See- "Nivolumab versus Everolimus in Advanced Renal-Cell Carcinoma"- Robert J. Motzer, M.D., Bernard Escudier, M.D., David F. McDermott, M.D., et.,al., for the CheckMate 025 Investigators. September 25, 2015. DOI: 10.1056/NEJMoa1510665.